Upon commencement of the GLP toxicology study, CytomX will receive a $15 million milestone payment from AbbVie as part of the 2016 strategic oncology collaboration between the companies.
The aim is to obtain more efficient products for patients. “Allogenic cell therapies using CAR-T open a major field of innovation in the treatment of cancer,” stated Patrick
The safety profile of anacetrapib in the early analysis was generally consistent with that demonstrated in previous studies of the drug, including accumulation of anacetrapib in adipose tissue,
Pembrolizumab (Keytruda) for lung cancer and olaratumab (Lartruvo) for sarcoma are now available on the CDF while more data is gathered on their value. Changes NICE made to
Mitoconix Bio is pioneering a novel strategy to improve mitochondrial function as a disease-modifying therapeutic for treating neurodegenerative disorders, including Huntington's, Parkinson's and Alzheimer's diseases. Proceeds from the
The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the
“The hope that Lenti-D may benefit boys facing such a devastating disease inspires all of us at bluebird,” said David Davidson, M.D., chief medical officer, bluebird bio. “Having
In accordance with the FDA's standard review designation, the agency has established a user fee goal date under the Prescription Drug User Fee Act (PDUFA) of February 12,
Founding investor Versant Ventures co-led the round with MPM Capital. They were also joined by other syndicate investors including Fonds de solidarité FTQ, Celgene Switzerland, an affiliate of
Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.